Aspirin use and survival after the diagnosis of breast cancer: A population-based cohort study

British Journal of Cancer

Volumn 111, Issue 3, 2014, Pages 623-627

  Fraser, D M ^a   Sullivan, F M ^b   Thompson, A M ^c   McCowan, C ^d  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POPULATION BASED CASE CONTROL STUDY; PRESCRIPTION; PRIORITY JOURNAL; SOCIAL STATUS; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84905225509     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.264     Document Type: Article

References (28)

1. Bardia A, Olson J, Vachon C, Lazovich D, Vierkant R, Wang A, Limburg P, Anderson K, Cerhan J (2011) Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study. Breast Cancer Res Treat 126(1): 149-155.
2. Bhattacharyya M, Girish GV, Ghosh R, Chakraborty S, Sinha AK (2010) Acetyl salicyclic acid (aspirin) improves synthesis of maspin and lowers incidence of metastasis in breast cancer patients. Cancer Sci 101(10): 2105-2109.
3. Blair CK, Sweeney C, Anderson KE, Folsom AR (2007) NSAID use and survival after breast cancer diagnosis in post-menopausal women. Breast Cancer Res Treat 101(2): 191-197.
4. Copson E, Eccles B, Maishman T, Gerty S, Stanton L, Cutress RI, Altman DG, Durcan L, Simmonds P, Lawrence G, Jones L, Bliss J, Eccles D, Group PSS (2013) Prospective observational study of breast cancer treatment outcomes for UK women aged 18-40 years at diagnosis: The POSH Study. J Natl Cancer Inst 105: 978-988.
5. Fein O (1995) The influence of social class on health status. J Gen Intern Med 10(10): 577-586.
6. Friis S, Thomassen L, Sørensen HT, Tjønneland A, Overvad K, Cronin-Fenton DP, Vogel U, McLaughlin JK, Blot WJ, Olsen JH (2008) Nonsteroidal anti-inflammatory drug use and breast cancer risk: a Danish cohort study. Eur J Cancer Prev 172: 88-96.
7. Gill JK, Maskarinec G, Wilkens LR, Pike MC, Henderson BE, Kolonel LN (2007) Nonsteroidal antiinflammatory drugs and breast cancer risk: the Multiethnic Cohort. Am J Epidemiol 166(10): 1150-1158.
8. Gupta RA, DuBois RN (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 1(1): 11-21.
9. Harris R, Beebe-Donk J, Alshafie G (2006) Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 6(1): 27.
10. Harris RE, Chlebowski RT, Jackson RD, Frid DJ, Ascenseo JL, Anderson G, Loar A, Rodabough RJ, White E, McTiernan A (2003) Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the women's health initiative. Cancer Res 63(18): 6096-6101.
11. Hoellen F, Kelling K, Dittmer C, Diedrich K, Friedrich M, Thill M (2011) Impact of cyclooxygenase-2 in breast cancer. Anticancer Res 31(12): 4359-4367.
12. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE (2010) Aspirin intake and survival after breast cancer. J Clin Oncol 28(9): 1467-1472.
13. Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE (2007) A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 99(8): 608-615.
14. Kirsh VA, Kreiger N, Cotterchio M, Sloan M, Theis B (2007) Nonsteroidal antiinflammatory drug use and breast cancer risk: subgroup findings. Am J Epidemiol 166(6): 709-716.
15. Kulendran M, Salhab M, Mokbel K (2009) Oestrogen-synthesising enzymes and breast cancer. Anticancer Res 29(4): 1095-1109.
16. Mackenbach JP, Bos V, Andersen O, Cardano M, Costa G, Harding S, Reid A, Hemström Ö, Valkonen T, Kunst AE (2003) Widening socioeconomic inequalities in mortality in six Western European countries. Int J Epidemiol 32(5): 830-837.
17. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Moller H (2009) Cancer prevalence in the United Kingdom: estimates for 2008. Br J Cancer 101(3): 541-547.
18. Makubate B, Donnan PT, Dewar JA, Thompson AM, McCowan C (2013) Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality. Br J Cancer 108(7): 1515-1524.
19. Marmot MG (2003) Understanding social inequalities in health. Perspect Biol Med 46(3 Suppl): S9-S23.
20. Morant SV, McMahon AD, Cleland JGF, Davey PG, MacDonald TM (2004) Cardiovascular prophylaxis with aspirin: costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 57(2): 188-198.
21. Phillips I, Langley R, Gilbert D, Ring A (2013) Aspirin as a treatment for cancer. Clin Oncol (R Coll Radiol (Great Britain)) 25(6): 333-335.
22. Rostom A, Dubé C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D (2007) Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med 146(5): 376-389.
23. Rozic JG, Chakraborty C, Lala PK (2001) Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 93(4): 497-506.
24. Schreinemachers DM, Everson RB (1994) Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 5(2): 138-146.
25. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN (1998) Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res 58(2): 362-366.
26. Takkouche B, Regueira-Méndez C, Etminan M (2008) Breast cancer and use of nonsteroidal anti-inflammatory drugs: a meta-analysis. J Natl Cancer Inst 100(20): 1439-1447.
27. Yeomans ND (2011) Aspirin: old drug, new uses and challenges*. J Gastroenterol Hepatol 26(3): 426-431.
28. Zou Z, Anisowicz A, Hendrix M, Thor A, Neveu M, Sheng S, Rafidi K, Seftor E, Sager R (1994) Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 263(5146): 526-529.